Open Source Securities released a research report on April 26 stating that it gave Bide Pharmaceutical (688073.SH) a purchase rating. The main reasons for the rating include: 1) accelerating the global layout and continuing high growth in overseas business; 2) molecular block SKU, which serves a steady growth in the number of customers. (Mainichi Keizai Shimbun)
开源证券4月26日发布研报称，给予毕得医药（688073.SH）买入评级。评级理由主要包括：1）加速全球化布局，海外业务持续高增长；2）分子砌块SKU，服务客户数量稳健增长。（每日经济新闻）
Open Source Securities released a research report on April 26 stating that it gave Bide Pharmaceutical (688073.SH) a purchase rating. The main reasons for the rating include: 1) accelerating the global layout and continuing high growth in overseas busines
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated